Jefferies analyst Peter Welford raised the firm’s price target on GSK to $53 from $52.50 and keeps a Buy rating on the shares. Q2 sales and profits should be broadly in-line with consensus and the 2024 outlook could be raised again when the company reports on July 31, the analyst tells investors in a preview note for the EU pharma group.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GSK:
- GSK Pharma call volume above normal and directionally bullish
- GSK, Pfizer under pressure after CDC narrows RSV shots age recommendation
- Elevation Oncology to evaluate combination in gastroesophageal junction cancer
- GSK, Pifzer RSV franchises ‘delivered a blow,’ says Citi
- GSK drops 1% in premarket trading after CDC updates RSV vaccination guidance